Treatment strategies for renal medullary carcinoma and epithelioid sarcoma
Pavlos Msaouel, Oncologist in Houston, University of Texas, shared a post by Ravin Ratan, Associate Professor in the Department of Sarcoma Medical Oncology at MD Anderson Cancer Center on X:
“Such a pleasure to activate this trial with Ravin Ratan and our sarcoma group MD Anderson Cancer Center. Rotating in his clinic as a fellow is the perfect experience for anyone interested in rare cancers.”
Quoting Ravin Ratan’s post:
“Delighted to offer to patients this study of ubamatamab, a bispecific antibody targeting MUC16 in epithelioid sarcoma patients. An anecdotal response in ES was reported with this agent in 2022. ”
Excited to activate this week our fourth clinical trial designed for Renal Medullary Carcinoma . It will also separately enroll patients with epithelioid sarcoma, another rare but deadly cancer defined by loss of the SMARCB1 tumor suppressor.
This trial was informed by our discovery that 60-70% of RMC tumors express CA-125 (MUC16) and that a major resistance mechanism to immunotherapy is downregulation of MHC-I which can be bypassed by CD3-targeted bispecifics such as ubamatamab.
Authors: Pavlos Msaouel, Nizar M. Tannir, Becky Slack Tidwell, Tharakeswara K Bathala, Rahul A. Sheth, Priya Rao, Wei-Lien Wang, Linghua Wang, Jianjun Gao, Alexander J Lazar, Ravin Ratan, Elizabeth Miller, Thomas Uldrick, Priscila Goncalves, David Knorr.
It is also encouraging that there is already anecdotal clinical evidence that this approach can be effective in epithelioid sarcoma.
Authors: Gabriel Revon-Riviere, Rose Chami, Denise Mills, Ailish Coblentz, MDPriscila Goncalves, Sarah Cohen-Gogo, Nathalie Fiaschi, Elizabeth Miller, Mary Peterman, Israel Lowy, Baijun Kou, Michael Dobosz, Daniel A. Morgenstern.
As with all our previous trials, we have incorporated correlative and functional analyses to understand why the therapy does or does not work. This preparedness has allowed us thus far to accelerate discoveries that improve survival outcomes of our patients with RMC.
By working together and keep pushing, many histologies, including chromophobe and Translocation Kidney Cancer, will have dedicated clinical trials within the next 2-3 years. Our commitment to get the average survival of RMC to 5 years before 2030 stands.
Abstract IA028: Renal medullary carcinoma: Discovery and validation of tailored treatment strategies .”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023